Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.

Conclusion Enzalutamide demonstrated clinical activity and was well tolerated in patients with advanced AR-positive TNBC. Adverse events related to enzalutamide were consistent with its known safety profile. This study supports additional development of enzalutamide in advanced TNBC.
PMID: 29373071 [PubMed - as supplied by publisher]

Source: Clinical Breast Cancer - January 26, 2018 Category: Cancer & Oncology Authors: Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J Tags: J Clin Oncol Source Type: research